Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing

Pharmacotherapy

Volumn 25, Issue 11 I, 2005, Pages 1566-1591

  Busti, Anthony J ^a,b   Hooper, Justin S ^a,b   Amaya, Christopher J ^a,c   Kazi, Salahuddin ^b,d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c Harris Methodist Fort Worth Hospital   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antiinflammatory drugs; Bone wound; Immunomodulating drugs; Postoperative wound healing; Soft tissue wound

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CELECOXIB; CHLOROQUINE; CORTICOSTEROID; CORTISONE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETODOLAC; GOLD; IBUPROFEN; IMMUNOMODULATING AGENT; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KETOROLAC; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PENICILLAMINE; PLACEBO; PREDNISOLONE; TACROLIMUS; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG HALF LIFE; FRACTURE HEALING; HUMAN; IMMUNOMODULATION; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SURGICAL WOUND; TENSILE STRENGTH; WOUND DEHISCENCE; WOUND HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; CYCLOOXYGENASE INHIBITORS; FRACTURE HEALING; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ORTHOPEDIC PROCEDURES; SIALOGLYCOPROTEINS; SURGICAL PROCEDURES, OPERATIVE; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 27644458699     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11.1566     Document Type: Review

References (153)

1. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
2. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 2004;50:1959-66.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.
4. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39: 295-9.
5. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-α: California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
6. Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004;38:1206-11.
7. Kirsner RS, Bogensberger G. The normal process of healing. In: Kloth LC, McCulloch JM, eds. Wound healing: alternatives in management, 3rd ed. Philadelphia: EA. Davis Company, 2002:3-34.
8. Williams DT, Harding K. Healing responses of skin and muscle in critical illness. Crit Care Med 2003;31(suppl):S547-57.
9. Robson MD, Heggers JP. Eicosanoids, cytokines, and free radicals. In: Cohen IK, Diegelmann RF, Lindblad WJ, eds. Wound healing: biochemical and clinical aspects. Philadelphia: WB. Saunders Co., 1992:292-304.
10. Leibovich SJ, Ross R. The role of the macrophage in wound repair: a study with hydrocortisone and antimacrophage serum. Am J Pathol 1975;78:71-100.
11. Bennett NT, Schultz GS. Growth factors and wound healing. II. Role in normal and chronic wound healing. Am J Surg 1993;166:74-81.
12. Glowacki J. Angiogenesis in fracture repair. Clin Orthop 1998;355(suppl):S82-9.
13. Wahl SM, Wong H, McCartney-Francis N. Role of growth factors in inflammation and repair. J Cell Biochem 1989;40:193-9.
14. Sims N, Baron R. Bone: structure, function, growth, and remodeling. In: Fitzgerald RH, Kaufer H, Malkani AL, eds. Orthopaedics. St. Louis: Mosby, 2002:156-7.
15. Bolander ME. Regulation of fracture repair by growth factors. Exp Biol Med 1992;200:165-70.
16. Gupta R, Caiozzo V, Cook SD, Barrack R, Skinner HB. Basic science in orthopedic surgery. In: Skinner HB, ed. Current diagnosis and treatment in orthopedics. New York: McGraw-Hill, 2003:8-9.
17. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture: an experimental study in rabbits. J Bone Joint Surg Br 1981;63:185-9.
18. Gerstenfeld LC, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003;21:670-5.
19. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.
20. Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 2002;99:9656-61.
21. Street JT, Wang JH, Wu QD, Wakai A, McGuinness A, Redmond HP. The angiogenic response to skeletal injury is preserved in the elderly. J Orthop Res 2001;19:1057-66.
22. Kuwano T, Nakao S, Yamamoto H, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 2004;18:300-10.
23. Pollack SV. Systemic medications and wound healing, Intl J Derm 1982;21:489-96.
24. Karukonda SR, Flynn TC, Boh EE, et al. The effects of drugs on wound healing. II. Specific classes of drugs and their effect on healing wounds. Int J Derm 2000;39:321-33.
25. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
26. Dunham BM, Hechtman HB, Valeri CR, et al. Anti-inflammatory agents inhibit hamster microvascular permeability induced by stimulated human polymorphonuclear leukocytes. Microcirc Endothelium Lymphatics 1984;1:465-89.
27. Murota S, Chang WC, Abe M, et al. The stimulatory effect of prostaglandins on production of hexoamine-containing substances by cultured fibroblasts. Prostaglandins 1976;12:93-195.
28. Murota S, Abe M, Otsuka K, et al. Stimulative effect of prostaglandins on production of hexosamine-containing substances by cultured fibroblasts. III. Induction of hyluronic acid synthetase prostaglandin F2α. Prostaglandins 1977;14:983-91.
29. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med 1999;5:1418-23.
30. 2: mediators of wound healing. Isr J Med Sci 1987;23:841-3.
31. Lee KH. Studies on the mechanism of action of salicylate. II. Retardation of wound healing by aspirin. J Pharm Sci 1968;57:1042-3.
32. Haws MJ, Kucan JO, Roth AC, Suchy H, Brown RE. The effects of chronic ketorolac tromathamine (Toradol) on wound healing. Ann Plast Surg 1996;37:147-51.
33. Carlstedt CA, Madsen K, Wredmark T. The influence of indomethacin on collagen synthesis during tendon healing in the rabbit. Prostaglandins 1986;32:353-8.
34. Dvivedi S. Effect of ibuprofen and diclofenac sodium on experimental wound healing. Indian J Exp Biol 1997;35: 1243-5.
35. Dong YL, Declan F, Van TZ, Herndon DN, Waymack JP. Effect of ibuprofen on the inflammatory response to surgical wounds. J Trauma 1993;35:340-3.
36. Riley GP, Cox M, Harrall RL, et al. Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro. J Hand Surg [Br] 2001;26:224-8.
37. Connelly CS, Panush RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991;151:1963-6.
38. Malan TP, Marsh G, Grossman E, et al. Evaluation of the opioid-sparing effectiveness of parecoxib sodium, a new COX-2 specific inhibitor, in the management of postoperative pain following total hip arthroplasty [abstr]. J Pain Symptom Manag 2001;2(suppl 1):38.
39. Gimbel JS, Brugger A, Zhao W, et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001;23:228-40.
40. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996;98:2076-85.
41. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-97.
42. Blomme EG, Chinn KS, Hardy MM, et al. Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol 2003;148:211-23.
43. Muscara MN, McKnight W, Asfaha S, Wallace JL. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol 2000;129:681-6.
44. Reuben SS, Maciolek H, Parker RK, et al. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty [abstr]. Reg Anesthesia Pain Med 2001;26:49.
45. Ro J, Sudmann E, Marton PF. Effect of indomethacin on fracture healing in rats. Acta Orthop Scand 1976;47:588-99.
46. Keller J, Bayer-Kristensen I, Bak B, et al. Indomethacin and bone remodeling. Acta Orthop Scan 1989;60;119-21.
47. Ho ML, Chang JK, Wang GJ. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop 1985;313:270-8.
48. Lindholm TS, Tornkvist H. Inhibitory effect on bone formation and calcification exerted by the anti-inflammatory drug ibuprofen. Scand J Rheumatol 1981;10:38-42.
49. Riew KD, Long J, Rhee J, et al. Time-dependent inhibitory effects of indomethacin on spinal fusion. J Bone J Surg Am 2003;85:632-4.
50. Glassman SD, Rose SM, Dimar JR, et al. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998;23:834-8.
51. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.
52. Elder C, Dahners LE, Weinhld PS. A cyclooxygenase-2 inhibitor impairs ligament healing in the rat. Am J Sports Med 2001;29:801-5.
53. Endo K, Sairyo K, Komatsubara S, et al. Cyclooxygenase-2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 2002;21:235-8.
54. Gerstenfeld LC, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J OrthopRes 2003;21:670-5.
55. Brown KM, Saunders MM, Kirsch T, et al. Effect of COX-2 specific inhibition on fracture healing in the rat femur. J Bone Joint Surg Am 2004;86-A:116-23
56. Kawai S. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal antiinflammatory drugs: a clinical consideration, Inflamm Res 1998;47(suppl 2):S102-6.
57. Brzozowski T, Konturek PC, Konturek SJ, et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 2001;53:343-53.
58. Wang JY, Yamasaki S, Takeuchi K, Okabe S. Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. Gastroenterology 1989;96(2 pt 1):393-402.
59. Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 1998;286;1383-90.
60. 2. Endocrinology 1992;130:443-8.
61. Baggott JE, Morgan SL, Ha TS, et al. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 1993;11:(suppl 8):101-5.
62. Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
63. Chabner BA, Allegra CA, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
64. Jolivet J, Schilsky RL, Bailey BD, et al. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 1982;70:351-60.
65. Rosandich PA, Kelley JT, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004;16:192-8.
66. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995;22:218-23.
67. Wluka A, Buchbinder R, Mylvaganam A, et al. Long-term methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol 2000;27:1864-71.
68. Sperling, RI, Coblyn JS, Larkin JK, et al. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990;33:1149-55.
69. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
70. Cronstein BN, Levin RI, Belanoff J, et al. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;78:760-70.
71. O'Callaghan JW, Forrest MJ, Brooks PM. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int 1988;8:41-5.
72. Walsdorfer U, Christophers E, Schroder JM. Methotrexate inhibits polymorphonuclear leukocyte chemotaxis in psoriasis. J Dermatol 1983;108:451-6.
73. Singh G, Fries JF, Williams CA, et al. Toxicity profiles of disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
74. Clerc D, Brousse O, Mariette X, et al. Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low-dose methotrexate and prednisone [letter]. Ann Rheum Dis 1991;50:67.
75. Cornelissen JJ, Bakker LJ, van der Veen MJ, et al. Nocardia asteroides pneumonia complicating low-dose methotrexate treatment of refractory rheumatoid arthritis. Ann Rheum Dis 1991;50:642-4.
76. Gispen JG, Alarcon GS, Johnson JJ, et al. Toxicity to methotrexate in rheumatoid arthritis. J Rheumatol 1987;14:74-9.
77. Antonelli MAS, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991;90:295-8.
78. Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. Thorax 1991;46:936-7.
79. Perruquet JL, Harrington TM, David DE. Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis [letter]. Arthritis Rheum 1983;26:1291-2.
80. Furst DE, Erikson N, Clute L. Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990;17:1628-35.
81. Jain A, Witbreuk M, Ball C, et al. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg [Am] 2002;27A:449-55.
82. Escalante A, Beardmore TD. Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol 1995;22:1844-51.
83. Perhala RS, Wilke WS, Clough JD, et al. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991;34:146-52.
84. Kasdan ML, June L. Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand. Orthopedics 1993;16:1233-5.
85. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214-17.
86. Sany J, Anaya JM, Canovas F, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993;20: 1129-32.
87. Bridges SL, Lopez-Mendez A, Han KH, Tracy IC, Alarcon GS. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991;18:984-8.
88. Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 1996;19:207-10.
89. Bamert W, Stojan B, Weidman V. D-penicillamine and wound healing in patients with rheumatoid arthritis. Z Rheumatol 1980;39:9-13.
90. Schorn D, Mowat AG. Penicillamine in rheumatoid arthritis: wound healing, skin thickness, and osteoporosis. Rheum Rehab 1977;16:223-30.
91. Arumugam S, Nimmannit S, Enquist IF. The effect of immunosuppression on wound healing. Surg Gynecol Obstet 1971;133:72-4.
92. 4. J Clin Invest 1980;65:1069-76.
93. Nimni ME, Bavetta LA. Collagen defect induced by penicillamine. Science 1965;150:905-7.
94. Youssef SA, Geever EF, Levenson SM. Penicillamine effect on wound healing. Surg Forum 1966;17:89-90.
95. Francis MJO, Mowat AG. Effects of D-penicillamine on skin collagen in man. Postgrad Med J 1974;50(suppl 2):30-2.
96. Harris E, Jaffe I, Sjoerdsma A. Effect of penicillamine on collagen in man. Arthritis Rheum 1966;9:509.
97. Kivirikko KI, Risteli L. Biosynthesis of collagen and its alterations in pathological states. Med Biol 1976;54:159-86.
98. Peacock EE. Control of wound healing and scar formation in surgical patients. Arch Surg 1981;116:1325-9.
99. Schorn D, Francis MJ, Loudon M, et al. Skin collagen biosynthesis in patients with rheumatoid arthritis treated with D-penicillamine. Scand J Rheumatol 1979;8:124-8.
100. Colombel JF, Loftus EV, Tremaine WJ, et al. Early post-operative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99: 878-83.
101. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003;134:565-73.
102. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-α inhibition therapy. Foot Ankle Int 2004;25:331-5.
103. Topstad DR, Panaccione R, Heine JA, et al. Combined seton placement, infliximab infusion and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease. Dis Colon Rectum 2003;46:577-83.
104. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi PG. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-27.
105. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
106. Aventis Pharmaceuticals. Arava (leflunomide) package insert. Kansas City, MO: 2001.
107. Fox RI, Herrmann ML, Costakis GF, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
108. Rückemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
109. Cao WW, Kao PN, Aoki Y, et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-β 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996;28:3079-80.
110. Hamilton L, Vojnovic I, Bakhle Y, et al. The anti-inflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-2 or iNOS [abstr], Proc Br Pharmacol Soc 1996;18:C51.
111. Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996;28:3086-7.
112. van Riel PLCM, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol 2004;31(suppl 71):21-4.
113. Immunex Corp. Enbrel (etanercept) package insert. Thousand Oaks, CA; 2004.
114. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11:277-85.
115. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
116. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
117. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol 2003;30:2563-71.
118. Centocor, Inc. Remicade (infliximab) package insert. Malvern, PA; 2004.
119. Amgen Inc. Kineret (anakinra) package insert. Thousand Oaks, CA; 2004.
120. Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 2004;50:1752-60.
121. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Resp Crit Care Med 1996;154(suppl):21-7.
122. Schwiebert LM, Beck LA, Stellato C, et al. glucocorticoid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol 1996;97:143-52.
123. Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Clin Invest 1971;50:2541-9.
124. Alvarez OM, Levendorf KD, Smerbeck RV, et al. Effect of topically applied steroidal and nonsteroidal anti-inflammatory agents on skin repair and regeneration. Fed Proc 1984;43: 2793-8.
125. Phillips K, Arffa R, Cintron C, et al. Effect of prednisolone and medroxyprogesterone on corneal wound healing, ulceration and neovascularization. Arch Ophthalmol 1983;101:640-3.
126. Oxlund H, Fogdestam I, Viidik A. The influence of Cortisol on wound healing of the skin and distant connective tissue response. Surg Gynecol Obstet 1979;148:876-80.
127. Waters RV, Gamradt SC, Asnis P, et al. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. Acta Orthop Scand 2000;71:316-21.
128. Lenco W, McKnight M, MacDonald AS. Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epitheliaiization in rabbits. Ann Surg 1975;181:67-73.
129. Manthorpe R, Garbarsch C, Lorenzen I. Glucocorticoid effect on repair processes in vascular connective tissue. Acta Endocrinologies 1975;80:380-97.
130. Ehrlich HP, Tarver H, Hunt TK. Effects of vitamin A and glucocorticoids upon inflammation and collagen synthesis. Ann Surg 1973;177:67-73.
131. Green JP. Steroid therapy and wound healing in surgical patients. Br J Surg 1965;52:523-5.
132. Garner RW, Mowat AG, Hazleman BL. Wound healing after operations on patients with rheumatoid arthritis. J Bone Joint Surg Br 1973;55:134-44.
133. Cracchiolo A, Cimino WR, Lian G. Arthrodesis of the ankle in patients who have rheumatoid arthritis. J Bone Joint Surg Am 1992;74:903-9.
134. Kondo H, Abe T, Hashimoto H, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double-blind, placebo controlled dose-finding study. J Rheumatol 2004;31:243-51.
135. Kremer JM, Habros JS, Kolba KS, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 2003;14:2763-8.
136. Drosos AA. Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. Drugs 2002;62:891-907.
137. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
138. Wells G, Haguenauer D, Shea B, et al. Cyclosporine for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2):CD001083.
139. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11(suppl 8):S117-19.
140. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003;3:1128-34.
141. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77:1556-61.
142. Zeeh J, Inglin R, Baumann G, et al. Mycophenolate mofetil impairs healing of left-sided colon anastomoses. Transplantation 2001;71:1429-35.
143. Wymenga AB, van Horn J, Theeuwes A, et al. Perioperative factors associated with septic arthritis after arthroplasty: prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand 1992;63:665-71.
144. Murray RP, Bourne MH, Fitzgerald RH. Metachronous infections in patients who have had more than one total joint arthroplasty. J Bone Joint Surg Am 1991;73:1469-74.
145. McConkey B, Fraser GM, Bligh AS. Transparent skin and osteoporosis: a study in patients with rheumatoid disease. Ann Rheum Dis 1965;24:219-23.
146. Mongan ES, Cass RM, Jacox RF, Vaughan JH. A study of the relation of seronegative and seropositive rheumatoid arthritis to each other and to necrotizing vasculitis. Am J Med 1969;47:23-5.
147. Gottrup F, Andreassen TT. Healing of incisional wounds in stomach and duodenum: the influence experimental diabetes. J Surg Res 1981;31:61-8.
148. Nasy S, Redei A, Karady S. Studies on granulation tissue production in alloxan-diabetic rats. J Endocrinol 1961;22: 143-6.
149. Andreassen TT, Oxlund H. The influence of experimental diabetes and insulin treatments on the biochemical properties of rat skin incisional wounds. Acta Chir Scand 1987;153:405-9.
150. Karukonda SR, Flynn TC, Boh EE, et al. The effects of drugs on wound healing: part 1. IntlJ Derm 2000;39:250-7.
151. Esterly NB, Furey NL, Flanagan LE, et al. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978;70:51-5.
152. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34.
153. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002;287:236-40.